Page 50 - Read Online

Hall et al. Hepatoma Res. 2026;12:20 Page 11 of 15

broader clinical applicability.

Despite encouraging results, challenges remain in optimizing patient selection and therapeutic sequencing in
the real-world setting. Variability in practice patterns, access to specialized care, and multidisciplinary
collaboration can influence outcomes, emphasizing the importance of coordinated care pathways involving
interventional radiologists, hepatologists, medical oncologists, and radiation oncologists. Enhanced
communication and integrated treatment planning are vital to tailor therapies based on individual patient
characteristics, tumor biology, and response dynamics.

Future research priorities
Biomarkers for precision medicine
A pressing priority is the identification and validation of robust molecular and immune biomarkers that
predict response or resistance to Y-90 combination therapies. Beyond conventional clinical markers such as
AFP, emerging genomic and transcriptomic signatures, immune cell infiltration patterns, and circulating
tumor DNA profiles hold promise for refining patient stratification. Such biomarkers could facilitate early
identification of responders, guide adaptive treatment modifications, and inform novel agent selection,
ultimately enabling a more personalized therapeutic approach.

Integration of novel agents
The evolving landscape of systemic therapies presents opportunities to enhance Y-90 combinations by
incorporating next-generation agents. Dual immune checkpoint blockade targeting PD-1/PD-L1 and
CTLA-4 pathways, adoptive cell therapies such as chimeric antigen receptor (CAR) T cells or TILs, and
agents targeting the fibrotic tumor microenvironment may act synergistically with radiation-induced
immunogenic effects. Investigating these combinations could overcome immune evasion mechanisms and
potentiate durable antitumor responses, particularly in immunologically “cold” tumors refractory to
conventional immunotherapy.

Elucidation of resistance mechanisms
A deeper mechanistic understanding of intrinsic and acquired resistance to both Y-90 and systemic therapies
is essential. Tumor heterogeneity, hypoxia-driven angiogenesis, immune suppressive microenvironments,
and molecular escape pathways all contribute to treatment failure. Advanced preclinical models and
translational studies focusing on tumor-stroma interactions, immune checkpoint dynamics, and angiogenic
signaling would enable the design of combination regimens aimed at circumventing resistance.

Multidisciplinary care models
Future clinical success will hinge on the development and implementation of multidisciplinary care
frameworks that integrate expertise across specialties. Streamlined coordination can optimize timing and
sequencing, proactively manage adverse effects, and enhance patient adherence and quality of life.
Additionally, embedding real-time biomarker monitoring and adaptive trial designs within clinical
workflows may accelerate the translation of mechanistic insights into improved therapeutic outcomes.

CONCLUSION
Y-90 radioembolization combined with systemic therapies, particularly targeted agents and ICIs, represents
an evolving and promising strategy in the management of HCC. These combination approaches harness
synergistic mechanisms - radiation-induced tumor cytotoxicity and vascular disruption, suppression of
angiogenic escape through tyrosine kinase inhibition, and reinvigoration of antitumor immunity via
checkpoint blockade - to enhance both local control and systemic efficacy.